Home / GLP-1 appeals / Zepbound
Zepbound (tirzepatide) denials
Your insurance denied Zepbound. Here is how to appeal it.
Zepbound denials have surged since Aetna removed it from coverage in July 2025. If you were cut off, or your plan never covered it, there are specific appeal paths, including a sleep apnea angle many patients do not know about. We draft your appeal for free, grounded in your plan's own rules with every citation verified. You review, sign, and file it.
Free to draft. Every citation checked against your plan's own rules before you file.
Your deadline
Often 60 to 180 days
From the denial date for your plan's first internal appeal. Your denial notice controls, check it.
Common reasons
Mostly administrative
Missing prior auth, step therapy, obesity criteria not documented, a formulary cut, or an exclusion.
What wins
Cite the right indication
Mapping to the plan's published criteria, and the sleep apnea indication where it applies, beats generic letters.
Aetna removed Zepbound from coverage effective July 1, 2025. If you were covered by Aetna and lost your Zepbound coverage at that date, you are part of a large group in the same situation. There are specific appeal angles, including a continuity-of-care argument and, if you have a sleep apnea diagnosis, a separate FDA indication that may fall outside the coverage cut. Check your specific situation here.
Why Zepbound gets denied
Zepbound (tirzepatide) received FDA approval in November 2023 for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related comorbidity. In June 2024, the FDA approved a second indication: treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. The SURMOUNT-OSA trial documented significant reduction in sleep apnea severity and weight in this population. That second indication matters for appeals in a way many patients are not aware of: some plans with a blanket anti-obesity exclusion, or that cut Zepbound as a weight management drug, may not have updated their criteria to address the sleep apnea indication, which is a respiratory-disease treatment, not a weight management treatment. The denials cluster into a handful of patterns:
- Obesity criteria not explicitly documented. Plans require BMI of 30 or higher, or 27 plus a qualifying comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). If your chart notes did not use the plan's specific threshold language, automated review can flag it as non-qualifying even when you clearly meet the criteria.
- Step therapy, document prior weight management attempts. Many plans require documented failure of structured lifestyle interventions or a preferred anti-obesity medication before approving Zepbound. If the prior authorization did not include this history, even if you tried other approaches, the plan triggers a step-therapy denial.
- Prior authorization lapsed or was never filed. Zepbound requires prior authorization. A PA that expired at plan renewal, a PA missing supporting documentation, or a PA never filed before the prescription was filled is one of the most common and most fixable denial types.
- A formulary coverage cut. Aetna removed Zepbound from its covered drug formulary effective July 1, 2025. If you lost coverage at that date, two appeal angles exist: continuity-of-care (documenting the clinical harm of interrupting established treatment) and the sleep apnea indication, if applicable, which may fall outside the weight-management coverage removal.
- Blanket anti-obesity medication exclusion. Some employer plans exclude all anti-obesity medications. If that is your situation, the primary appeal angle is the sleep apnea indication: Zepbound's June 2024 FDA approval for obstructive sleep apnea positions it as a respiratory-disease treatment, which may fall outside an anti-obesity exclusion.
- Zepbound vs. Mounjaro confusion. Mounjaro and Zepbound are both tirzepatide from Eli Lilly with different FDA indications. Mounjaro is approved for type 2 diabetes; Zepbound for obesity and sleep apnea. If the prior authorization cited the wrong indication or the wrong drug, the denial may be a coding error rather than a clinical or coverage decision.
How to appeal it
For Zepbound, the winning move adds one step: identify the right indication before you map the criteria. If you have a documented sleep apnea diagnosis, that indication is often a stronger path than the obesity indication, especially under an anti-obesity exclusion.
The move: decide whether to appeal as an obesity case or a sleep apnea case (or both), pull the plan's matching coverage policy, then show line by line where your records meet each criterion. If your plan cut Zepbound at a formulary change, add a continuity-of-care argument documenting the harm of interrupting established, effective treatment.
Read the denial letter and identify the reason
The letter states a reason and a deadline. Note both, and the coverage-policy number cited. If the denial came at renewal after a formulary change, note that the reason is a formulary change, not a clinical judgment.
Decide which indication to appeal: obesity or sleep apnea
If you have a documented obstructive sleep apnea diagnosis and you are on CPAP therapy or have been evaluated for sleep apnea, the sleep apnea indication (approved June 2024) may be a stronger path than the obesity indication, especially under an anti-obesity exclusion. Your prescriber will need to document that indication explicitly.
Pull your plan's coverage criteria for that indication
Find the coverage policy for anti-obesity medications or, if applicable, for obstructive sleep apnea treatments. These are on the insurer's provider portal or available by request. Plans may not yet have a Zepbound sleep apnea policy, and that gap can itself support the appeal.
Gather supporting documentation
For obesity: BMI and weight history, comorbidity diagnoses, prior weight management interventions, prescriber notes. For sleep apnea: AHI score, sleep study results, CPAP adherence or failure documentation, comorbid obesity diagnosis. The goal is paper documentation for every criterion in the plan's policy.
Write the appeal and file before the deadline
For obesity, cite Zepbound's FDA approval (November 2023) and the SURMOUNT trials. For sleep apnea, cite the June 2024 FDA approval and SURMOUNT-OSA, and frame it as a respiratory-disease treatment if your plan has an anti-obesity exclusion. Map your facts to the plan's criteria, keep proof of filing, and calendar both the internal and external review deadlines.
The magic is visible
Your appeal, built from your plan's own rules. Every citation checked.
We draft from the sources below, then verify each one before you file. On our held-out testing: 0 invented citations, versus about 1 in 4 for raw AI.
Sample appeal, built from real source types
- Your plan's coverage policyThe specific anti-obesity or sleep apnea policy that applies to your planVerified
- FDA labelTirzepatide (Zepbound) prescribing information, indication and dosingVerified
- Your recordsYour BMI history or sleep apnea diagnosis and prior therapies, cited back accuratelyVerified
No source we can't show you. No citation we haven't checked. See it on your own denial, free.
Let's check your Zepbound denial, free.
Answer a few questions for an honest read on your odds and the right indication for your case, then your verified draft. No account, no cost.
Check my denial, freeZepbound denial: common questions
My plan dropped Zepbound. What are my options?
Can I appeal if my plan has a blanket anti-obesity exclusion?
What is the difference between Zepbound and Mounjaro?
How long do I have to appeal?
Is this really free?
Appeal your Zepbound denial by insurer
Pick your plan for its real deadlines, denial patterns, and the appeal strategy that works with it. Every page grounded in that insurer's own rules.
More on Zepbound denials
Was it a prior auth, or a specific denial reason? Start with the page that matches your letter.